Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,country,website,maxAge,address1,industry,address2
t0,HSITF,37037000.0,11088500,,,4305000,71000,4305000,572000,0,-2384000,-2384000,1812000,-39500,,,,0,0,2384000,0,6689000,,4305000,4305000,133384000.0,4272000.0,37037000.0,683000.0,41380000.0,5544000.0,-102902000.0,1011000.0,4960000.0,2805000.0,1546000.0,1011000.0,5000.0,37938000.0,3437000.0,125000.0,1467000.0,4000.0,1645000,-3000,1644000,1692500,1757500,-678500,65500,2107000,-57500,-1237000,1500,-12500,-500,-4849500,-1000,35133000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.56 - 1.56,1.56,finmb_25451671,Other OTC,Hadasit Bio-Holdings Ltd,ILS,892,0,0.7099999,0.835294,0.85 - 3.25,-1.69,-0.52000004,0.85,3.25,-14400000,False,False,USD,PRE,1.5445714,0.015428543,0.0099888835,2.019348,-0.45934796,-0.22747341,17298060,15,America/New_York,EDT,HBL - HADASIT BIO HOLDINGS LTD,1.56,1629389769,0.0,1.56,1.56,1.56,400,0,PNK,4,us_market,0.3,,,3.25,0.85,1.5446,2.0193,892,,11.09M,,2.28M,75.00%,0.00%,,,,,,,,,,,0.00%,,"Feb 05, 2019",1:10,"Jul 21, 2016","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-3.25%,146.54%,,,,,,,,,,,,8.59,13.52,,,,Value,91120,Healthcare,2,"Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.",Jerusalem,Israel,http://www.hbl.co.il,86400,Jerusalem Bio-Park,Biotechnology,5th Floor Hadassah Ein-Kerem Campus
t-1,HSITF,37037000.0,11088500,,,4305000,71000,4305000,572000,0,-2384000,-2384000,1812000,-39500,,,,0,0,2384000,0,6689000,,4305000,4305000,133384000.0,4272000.0,37037000.0,683000.0,41380000.0,5544000.0,-102902000.0,1011000.0,4960000.0,2805000.0,1546000.0,1011000.0,5000.0,37938000.0,3437000.0,125000.0,1467000.0,4000.0,1645000,-3000,1644000,1692500,1757500,-678500,65500,2107000,-57500,-1237000,1500,-12500,-500,-4849500,-1000,35133000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.56 - 1.56,1.56,finmb_25451671,Other OTC,Hadasit Bio-Holdings Ltd,ILS,892,0,0.7099999,0.835294,0.85 - 3.25,-1.69,-0.52000004,0.85,3.25,-14400000,False,False,USD,PRE,1.5445714,0.015428543,0.0099888835,2.019348,-0.45934796,-0.22747341,17298060,15,America/New_York,EDT,HBL - HADASIT BIO HOLDINGS LTD,1.56,1629389769,0.0,1.56,1.56,1.56,400,0,PNK,4,us_market,0.3,,,3.25,0.85,1.5446,2.0193,892,,11.09M,,2.28M,75.00%,0.00%,,,,,,,,,,,0.00%,,"Feb 05, 2019",1:10,"Jul 21, 2016","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-3.25%,146.54%,,,,,,,,,,,,8.59,13.52,,,,Value,91120,Healthcare,2,"Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.",Jerusalem,Israel,http://www.hbl.co.il,86400,Jerusalem Bio-Park,Biotechnology,5th Floor Hadassah Ein-Kerem Campus
t-2,HSITF,28039000.0,11088500,,,11304500,71000,11299000,578500,0,1724000,1724000,-2302500,-3000,,,,0,0,-1724000,0,9580500,,11304500,11299000,133231000.0,2611000.0,28039000.0,2327000.0,30721000.0,5526000.0,-111512000.0,794000.0,746000.0,2611000.0,,794000.0,6000.0,29307000.0,1408000.0,213000.0,,284000.0,120000,-2000,119000,1692500,-1000,-648000,65500,-611000,15500,-744500,2500,14500,-1000,-11410500,-1000,26696000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.56 - 1.56,1.56,finmb_25451671,Other OTC,Hadasit Bio-Holdings Ltd,ILS,892,0,0.7099999,0.835294,0.85 - 3.25,-1.69,-0.52000004,0.85,3.25,-14400000,False,False,USD,PRE,1.5445714,0.015428543,0.0099888835,2.019348,-0.45934796,-0.22747341,17298060,15,America/New_York,EDT,HBL - HADASIT BIO HOLDINGS LTD,1.56,1629389769,0.0,1.56,1.56,1.56,400,0,PNK,4,us_market,0.3,,,3.25,0.85,1.5446,2.0193,892,,11.09M,,2.28M,75.00%,0.00%,,,,,,,,,,,0.00%,,"Feb 05, 2019",1:10,"Jul 21, 2016","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-3.25%,146.54%,,,,,,,,,,,,8.59,13.52,,,,Value,91120,Healthcare,2,"Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.",Jerusalem,Israel,http://www.hbl.co.il,86400,Jerusalem Bio-Park,Biotechnology,5th Floor Hadassah Ein-Kerem Campus
t-3,HSITF,28039000.0,11088500,,,11304500,71000,11299000,578500,0,1724000,1724000,-2302500,-3000,,,,0,0,-1724000,0,9580500,,11304500,11299000,133231000.0,2611000.0,28039000.0,2327000.0,30721000.0,5526000.0,-111512000.0,794000.0,746000.0,2611000.0,,794000.0,6000.0,29307000.0,1408000.0,213000.0,,284000.0,120000,-2000,119000,1692500,-1000,-648000,65500,-611000,15500,-744500,2500,14500,-1000,-11410500,-1000,26696000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,1.56 - 1.56,1.56,finmb_25451671,Other OTC,Hadasit Bio-Holdings Ltd,ILS,892,0,0.7099999,0.835294,0.85 - 3.25,-1.69,-0.52000004,0.85,3.25,-14400000,False,False,USD,PRE,1.5445714,0.015428543,0.0099888835,2.019348,-0.45934796,-0.22747341,17298060,15,America/New_York,EDT,HBL - HADASIT BIO HOLDINGS LTD,1.56,1629389769,0.0,1.56,1.56,1.56,400,0,PNK,4,us_market,0.3,,,3.25,0.85,1.5446,2.0193,892,,11.09M,,2.28M,75.00%,0.00%,,,,,,,,,,,0.00%,,"Feb 05, 2019",1:10,"Jul 21, 2016","Dec 30, 2020","Dec 30, 2020",0.00%,0.00%,-3.25%,146.54%,,,,,,,,,,,,8.59,13.52,,,,Value,91120,Healthcare,2,"Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.",Jerusalem,Israel,http://www.hbl.co.il,86400,Jerusalem Bio-Park,Biotechnology,5th Floor Hadassah Ein-Kerem Campus
